Diabetic Ketoacidosis News and Research

RSS

Diabetic ketoacidosis – (DKA) or diabetic coma occurs when a diabetic does not properly balance their insulin intake with their diet or activity.

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

7 Oct 2009

Januvia in combination with metformin or taken alone lowers blood sugar

A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

29 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

Takeda receives FDA response regarding NDA for fixed-dose combination of alogliptin and ACTOS

Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).

4 Sep 2009

Every 3 minutes one person is diagnosed with diabetes

According to new research from Britain every three minutes one person in the UK is diagnosed with diabetes - these latest figures come from the leading health charity Diabetes UK and marks the organisation's 75th Anniversary.

7 Jan 2009

Parents who just prayed as child was dying charged with murder

The parents of a diabetic girl in the U.S. who died as her parents prayed for her recovery rather than seek medical help, have been charged with second-degree reckless homicide.

30 Apr 2008

Tredaptive and Janumet recommended for approval in European Union

Food and Drug Administration (FDA) is currently reviewing the combination of extended release (ER) niacin and laropiprant under the trademark Cordaptive (ER niacin/laropiprant). The CHMP recommendation does not apply to regulatory decisions by the FDA and no inferences should be made about pending FDA regulatory actions based on the recommendation of the CHMP.

24 Apr 2008

Efficient response in primary care would reduce the use of hospitals by seniors

Researchers from the Department of Preventive Medicine and Public Health from the University of Granada have carried out a study with patients over 60.

10 Mar 2008

Restricting insulin doses increases mortality risk in women with type 1 diabetes

A new study led by researchers at the Joslin Diabetes Center has found that women with type 1 diabetes who reported taking less insulin than prescribed had a three-fold increased risk of death and higher rates of disease complications than those who did not skip needed insulin shots.

28 Feb 2008

Use of general anesthesia for heroin detoxification offers no benefit when compared to two other methods

The use of general anesthesia for heroin detoxification offers no benefit when compared to two other methods, and is associated with several potentially life-threatening adverse events, according to an article in the August 24/31 issue of JAMA: The Journal of the American Medical Association.

23 Aug 2005

Researchers find way to detect dangerous brain swelling in diabetic children

A rare swelling of the brain that is nonetheless the most common diabetes-related cause of death for children with the disease could be caught earlier — potentially saving lives — if practitioners learn to recognize key signs, researchers at the University of Florida report.

18 Aug 2004